Objective:

To investigate daytime sleepiness during dCBT-I and evaluate its predictive value for treatment efficacy.

Approach:

Key Findings:

• ESS scores significantly increased at weeks 2, 4, and 6, peaking at week 2.
• Sex, medication use, snoring, and baseline ESS were significant influencing factors.
• Patients with early increased sleepiness showed greater PSQI reduction rates at subsequent follow-ups.
• Week 2 ESS exacerbation independently predicted higher PSQI reduction at weeks 4, 8, 12, and 16 (all p < 0.05).

Interpretation:

Increased daytime sleepiness often occurs in the early stage of dCBT-I and is related to multiple factors.

Limitations:

• The study is retrospective and may have inherent biases.
• The assessment tools rely on self-reported data, which can be subjective.

Conclusion:

Increased daytime sleepiness during early dCBT-I may indicate better treatment outcomes.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.